**AtTEnd**

Stage III/IV with residual disease or recurrent endometrial cancer
N=550

R 1:2

Paclitaxel 175mg/m² carboplatin AUC 5 or 6 Placebo for 6-8 cycles or PD

Maintenance placebo

Paclitaxel 175mg/m² carboplatin AUC 5 or 6 atezolizumab 1200mg for 6-8 cycles or PD

Maintenance atezo 1200mg

Confirmed PD

**Stratified by:**
- Country of the experimental center
- Histological type (endometrioid vs. other types)
- Disease (recurrent disease vs advanced disease at primary diagnosis)
- MS status (MSS vs MSI vs non-evaluable)